Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government. SVB Leerink says that the new contract implies the price per Comirnaty dose is ~$30.50. Comirnaty U.S. pricing per dose has increased from $19.50 (2020 contracts), to $24 (+23%; 2021 contract), and now to ~$30.50 (+27%). The analysts…

Benzinga

Pfizer Seeks Complete Approval For Paxlovid For High Risk COVID-19 Patients

Pfizer Inc (NYSE:PFE) has submitted a new drug application to the FDA for the approval of Paxlovid for patients at high risk for progression to severe illness from COVID-19. Paxlovid is currently authorized for emergency use to treat mild-to-moderate COVID-19 in adults and pediatric patients at high risk for progression to severe COVID-19,…

Benzinga

Will Palantir, Pfizer And Oracle Stocks Continue Higher In This Trend?

Oracle Corporation (NYSE: ORCL), Pfizer Inc (NYSE: PFE) and Palantir Technologies Inc (NYSE: PLTR) were all trading near to fla

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Tweaked COVID boosters in US must target newer omicron types

U.S. regulators are telling COVID-19 vaccine makers to tweak any booster doses intended for fall so they protect against the newest omicron relatives

The Independent UK

COVID vaccination reboot coming this fall to add tweaks for new coronavirus variants

The FDA will have to decide the exact recipe. But expect a combination shot that adds protection against omicron or some of its newer relatives to the original vaccine.

Chicago Sun-Times

Check Out What Whales Are Doing With PFE

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 18 strange trades.

Benzinga

Elmo, 3, joins youngest Americans in getting vaccinated

Elmo got a COVID-19 vaccine

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Efficacy Of Pfizer's Paxlovid COVID Drug Crashes, According To New NIH-Funded Study

A new National Institutes of Health (NIH) funded study sheds new light on the waning effectiveness of Pfizer’s (NYSE: PFE) Paxlovid to prevent patient hospitalizations due to COVID.

Benzinga

Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'

The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news, announced Tuesday, June 28, could have a big impact on the share prices of vaccine makers.

Benzinga

Revive Therapeutics Data Access Plan Approved By The FDA; Partial Unblinded Data In Company Hands

Revive Therapeutics Ltd. (OTC: RVVTF) moved closer towards potential endpoint change in their Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19.

Benzinga

Fauci suffers COVID symptom rebound after course of Pfizer’s Paxlovid

Anthony Fauci, the chief medical adviser to President Joe Biden, suffered a rebound of COVID-19 symptoms after taking Pfizer Inc.’s antiviral Paxlovid.

Tribune News Service

European Commission defiant over Von der Leyen’s Pfizer texts

EU executive defends its right not to keep records of president’s messages after rebuke from ombudsman

The Guardian - UK

South Korea approves first homemade COVID-19 vaccine

Health officials in South Korea have approved the country's first domestically developed COVID-19 vaccine for people 18 years or older, adding another public health tool in the fight against a prolonged pandemic

The Independent UK

Detroit makes COVID vaccines available for children 6 months to 5 years

DETROIT — The city is providing COVID vaccines from Pfizer and Moderna for children ages 6 months up to 5 years of age, following emergency authorization from the federal Food and Drug Administration and approval from the state health department.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

COVID shots should get omicron-targeted update, FDA advisers say

COVID-19 shots from Pfizer Inc. and Moderna Inc. should be updated to include components that target the highly transmissible omicron variant, the version of the virus that causes most of the world’s cases, U.S. regulatory advisers said.

The Conversation

Canada needs to invest more money into science innovation to help prevent the next global crisis

Canada has lagged behind its peer nations in innovation for decades. Currently, Canada is ranked 11th out of the 16 similarly developed countries assessed. While our “C” grade is a moderate improvement over our previous “D” grade, innovation still remains a barrier to high-quality job creation and economic prosperity in…

Benzinga

Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases

Roivant Sciences Ltd (NASDAQ:ROIV) and Pfizer Inc (NYSE:PFE) unveiled Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant was established in September 2021 through a transaction between Roivant and Pfizer. Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25%…

The Independent UK

US grapples with whether to modify COVID vaccine for fall

U.S. health authorities are facing a critical decision: whether to offer new COVID-19 booster shots this fall that are modified to better match the latest changes of the shape-shifting coronavirus

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US

US Covid-19 vaccine rollout for under-fives must overcome hesitancy

For many parents the availability of vaccination to the youngest age group is not before time but others plan to ‘wait and see’

Tribune News Service

Pfizer’s omicron booster improves immune response, company says

Pfizer’s two omicron-focused booster vaccines massively improve a person’s immune response against the COVID variant, the company said Saturday.

WEKU

Pfizer says its tweaked COVID-19 shots boost protection against the omicron variant

Pfizer said that tweaking its vaccine to better target the omicron variant is safe and works — just days before regulators debate whether to offer Americans updated booster shots this fall.

The Independent UK

Pfizer says tweaked COVID-19 shots boost omicron protection

Pfizer says tweaking its COVID-19 vaccine to better target the omicron variant is safe and boosts protection

The Conversation

Misinformation will be rampant when it comes to COVID-19 shots for young children – here's what you can do to counter it

When the Centers for Disease Control and Prevention endorsed both the Pfizer-BioNTech and Moderna COVID-19 vaccines for all children ages 6 months to 5 years on June 18, 2022, it opened the door for nearly 20 million children to get vaccinated.

The Independent UK

Experts endorse Moderna COVID-19 shots for kids ages 6 to 17

An expert panel backed a second COVID-19 vaccine option for kids ages 6 to 17

The Philadelphia Inquirer

Research behind COVID vaccines reaps close to $1 billion in royalties for Penn

PHILADELPHIA — The University of Pennsylvania has reaped extraordinary financial gain from COVID-19 vaccines — approaching $1 billion since the beginning of last year — thanks to patents on a process Penn researchers developed more than 15 years ago.

1 … 45 46 47 48

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

339 stories

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.